New Milliman Analysis Shows Medicare Part D Proposed Rule Could Increase Premiums More than It Saves in Cost Sharing for Majority of Beneficiaries
Brianna Jones Senior Manager, Research Brianna Jones is a Senior Manager, Research. Prior to joining PCMA, Ms. Jones worked as a Policy Analyst at the Patients for Affordable Drugs. Ms. Jones graduated with a B.A. in Political Science and Journalism
Employers and other health plan sponsor payers choose how they would like to compensate pharmacy benefit companies for the services and programs they provide.
Michelle Mack Director, State Affairs Michelle Mack is Director, State Affairs for PCMA. In this capacity, she advocates on behalf of PCMA’s member companies throughout the West and Midwest. She represents PCMA before governors, state legislators and regulators as well
Even including discounts, however, the company’s net profit margin for 2017 was 34 percent, its highest since at least 2000, when it was half that high.
A recent report from the Massachusetts Health Policy Commission used publicly available drug pricing data in an attempt to identify proxies to highlight the differences between what health plan sponsors reimburse their pharmacy benefit managers (PBM) for a prescription versus
Sam Hallemeier Senior Director, State Affairs Sam Hallemeier is Senior Director, State Affairs for PCMA. In this role he coordinates and supports state activity for the state affairs team and develops valuable resources for our members. Prior to PCMA, Mr.
Sanofi and Regeneron have agreed to lower the price of their cholesterol medicine in exchange for easier access for patients covered by pharmacy benefit manager
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on reports that twenty-eight drugmakers are set to raise prescription drug prices in 2019: “Today’s news underscores the fact that drugmakers alone set
©2024 PCMA. All Rights Reserved.
